fbpx
QQQ
+ 0.00
271.64
+ 0%
DIA
+ 0.00
265.46
+ 0%
SPY
+ 0.00
326.70
+ 0%
TLT
+ 0.00
160.70
+ 0%
GLD
+ 0.00
176.14
+ 0%

DEA Deschedules Expidiolex; GW Pharma's CBD Epilepsy Treatment No Longer A Controlled Substance

April 7, 2020 11:11 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

GW Pharmaceuticals plc (NASDAQ:GWPH) confirmed Monday it has obtained a notice from the Drug Enforcement Administration certifying that its Epidiolex oral solution has been descheduled and is no longer a controlled substance.

“This notification from DEA fully establishes that EPIDIOLEX, the only CBD medicine approved by FDA, is no longer a controlled substance under the federal Controlled Substances Act,” GW Pharma CEO Justin Gover said in a statement.

Gover thanked the DEA for confirming "the non-controlled status" of the medicine.

"Importantly, the descheduling of EPIDIOLEX has the potential to further ease patient access to this important therapy for patients living with Lennox-Gastaut Syndrome and Dravet syndrome, two of the most debilitating forms of epilepsy," he said.

Leer en Español: Epidiolex, la Droga con CBD para Epilepsia, se Abre Camino Legal

After obtaining the DEA notice, the Cambridge, U.K.-based company said it has filed a post-approval supplement with the FDA to lift the Schedule V designation from the drug. GW Pharma said it is now working on enforcing these amendments at the state level and via the Epidiolex distribution network.

Once all the changes have been enacted, the drug can be prescribed just like any other non-controlled medicine, with a prescription being valid for one year. 

This allows doctors to prescribe the drug more freely, without the demands of state prescription drug monitoring programs, according to GW. 

GW Pharma shares were trading 4.66% higher at $90.62 at the time of publication Tuesday.

Related Links:

GW Pharma Vet Ethan Russo Launches Endocannabinoid Startup

GW Pharma Obtains Exclusive UK Commercialization Rights To Sativex From Bayer

Photo courtesy of GW Pharmaceuticals.


Related Articles

Real Brands Closes Merger With Canadian American Standard Hemp

Real Brands Inc. (OTCPK: RLBD) confirmed Tuesday, it has finalized the acquisition of Canadian American Standard Hemp Inc. read more

Turning Point Brands Backs Cannabinoid Company Dosist With $15M

Turning Point Brands Inc. (NYSE: TPB) agreed to invest $15 million in Dosist, a cannabinoid company. The two companies opted to co-create a new CBD brand featuring thc-free products.  read more

The Week In Cannabis: Stocks Outperform, Michigan Shapes Up As New Leader, Celeb Brands Get Hot

Cannabis stocks traded up in a relatively slow news week, where celebrity brands grabbed headlines. read more

Working Moms Are Keeping CBD In The Medicine Cabinet

This article was originally published on Cannabis & Tech Today, and appears here with permission. Parenting is never an easy task — and that’s been true since the beginning of time. Raising a kid isn’t a job that can be taken lightly, and that only adds more stress to the situation. read more

CBD Oils 101: The Difference Between Full-Spectrum, Broad-Spectrum And Isolate

This article is originally published on Sunday Scaries. read more